Enhanced virtual crossmatch in intestinal transplantation: association with outcomes and application in practice

다국어 초록 (Multilingual Abstract)

Background: The presence of preformed donor-specific antibodies in recipient serum against anti-human leukocyte antigen is a significant risk factor that negatively affects the outcomes of intestinal transplantation. Avoiding high-risk intestinal transplantation by physical and virtual cross matches has had limited success due to time constraints and ineffective correlation, respectively.
Methods: We developed a guideline to improve the association between physical and virtual cross matches using the retrospective data of 56 consecutive primary adult isolated intestinal transplantations from a single center.
Results: The mean fluorescence intensity of 2,000 for positive donor-specific antibodies revealed the best association between physical and virtual cross matches among different cut-off values, but with an unacceptable false positive rate of 54%. An enhanced virtual cross match with the summation of the mean fluorescence intensity of each anti- human leukocyte antigen improved the association between physical and virtual cross matches, with a sensitivity of 83% and specificity of 98%.
Conclusions: This enhanced virtual cross match more effectively predicts high-risk intestinal transplantation and is a better substitute for physical cross-match than the current virtual cross match. It also helps to avoid ill-considered abandonment of intestinal transplantation that is unnecessarily deemed high risk based on a simple virtual cross match.

참고문헌 (Reference)

1 Bond G, "The impact of positive T-cell lymphocytotoxic crossmatch on intestinal allograft rejection and survival" 32 : 1197-1198, 2000

2 Thenmozhi M, "Survival analysis in longitudinal studies for recurrent events : applications and challenges" 7 : 253-260, 2019

3 Hawksworth JS, "Successful isolated intestinal transplantation in sensitized recipients with the use of virtual crossmatching" 12 (12): S33-S42, 2012

4 Moon JI, "Routine surveillance endoscopy and biopsy after isolated intestinal transplantation-revisiting the gold standard" 33 : e13684-, 2019

5 Kubal C, "Prospective monitoring of donor-specific anti-HLA antibodies after intestine/multivisceral transplantation : significance of de novo antibodies" 99 : e49-56, 2015

6 Cheng EY, "Prevalence and clinical impact of donor-specific alloantibody among intestinal transplant recipients" 101 : 873-882, 2017

7 Farmer DG, "Pretransplant predictors of survival after intestinal transplantation : analysis of a single-center experience of more than 100 transplants" 90 : 1574-1580, 2010

8 Abu-Elmagd KM, "Preformed and de novo donor specific antibodies in visceral transplantation : long-term outcome with special reference to the liver" 12 : 3047-3060, 2012

9 Abu-Elmagd KM, "Five hundred intestinal and multivisceral transplantations at a single center : major advances with new challenges" 250 : 567-581, 2009

10 Talayero P, "Donor-specific antibodies in pediatric intestinal and multivisceral transplantation : the role of liver and human leukocyte antigen mismatching" 24 : 1726-1735, 2018

11 Gerlach UA, "Clinical relevance of the de novo production of anti-HLA antibodies following intestinal and multivisceral transplantation" 27 : 280-289, 2014

12 Tsai HL, "Association between donor-specific antibodies and acute rejection and resolution in small bowel and multivisceral transplantation" 92 : 709-715, 2011

13 Twisk JW, "Applied analysis of recurrent events : a practical overview" 59 : 706-710, 2005

14 Moon JI, ""Stoma or no stoma" : first report of intestinal transplantation without stoma" 20 : 3550-3557, 2020